Glioblastoma multiforme (GB) is the most aggressive and frequent primary malignant tumor in the central nervous system (CNS), with unsatisfactory and challenging treatment nowadays. Current standard of care includes surgical resection followed by chemotherapy and radiotherapy. However, these treatments do not much improve the overall survival of GB patients, which is still below two years (the 5-year survival rate is below 7%). Despite various approaches having been followed to increase the release of anticancer drugs into the brain, few of them demonstrated a significant success, as the blood brain barrier (BBB) still restricts its uptake, thus limiting the therapeutic options. Therefore, enormous efforts are being devoted to the development of novel nanomedicines with the ability to cross the BBB and specifically target the cancer cells. In this context, the use of nanoparticles represents a promising non-invasive route, allowing to evade BBB and reducing systemic concentration of drugs and, hence, side effects. In this review, we revise with a critical view the different families of nanoparticles and approaches followed so far with this aim.

Original languageEnglish
Article number4960
Issue number19
Publication statusPublished - 10 Oct 2022


  • BBB
  • brain cancer
  • drug delivery
  • glioblastoma
  • nanoparticles
  • preclinical model


Dive into the research topics of 'Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?'. Together they form a unique fingerprint.

Cite this